Clinical Trial Detail

NCT ID NCT03193853
Title TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Baylor Research Institute
Indications

triple-receptor negative breast cancer

Therapies

Cisplatin + Nab-paclitaxel

MLN1117 + Sapanisertib

Age Groups: senior adult

No variant requirements are available.